Skip to Main Content
Table 3—

Association of Ser1369Ala genotype with percentage decrease in FPG, 2-h plasma glucose, and A1C after 8 weeks of gliclazide treatment in type 2 diabetic patients (pooled sample of cohort 1 and cohort 2)

Outcome phenotypeGenotypenBaselineDay 57Decrease (%)Regression, β (Se)*P
FPG (mmol/l) Ser/Ser 363 11.1 ± 2.9 7.9 ± 2.4 26.1 ± 20.2 — — 
 Ser/Ala 562 11.0 ± 2.9 7.6 ± 2.0 27.9 ± 18.9 2.8 (1.6) 0.076 
 Ala/Ala 224 11.5 ± 3.3 7.6 ± 2.5 31.6 ± 19.8 7.7 (1.9) <0.001 
2-h plasma glucose (mmol/l) Ser/Ser 269 18.9 ± 4.7 15.2 ± 5.9 22.3 ± 22.8 — — 
 Ser/Ala 404 18.4 ± 4.7 14.0 ± 4.1 23.3 ± 23.4 10.8 (3.3) 0.001 
 Ala/Ala 157 18.8 ± 4.4 13.9 ± 4.4 27.6 ± 20.3 11.9 (4.1) 0.003 
A1C (%) Ser/Ser 151 8.4 ± 1.9 7.0 ± 1.5 14.2 ± 17.6 — — 
 Ser/Ala 251 8.3 ± 2.0 6.8 ± 1.2 15.8 ± 15.3 1.9 (1.4) 0.195 
 Ala/Ala 106 8.7 ± 2.0 7.0 ± 1.4 17.4 ± 13.5 3.5 (1.8) 0.060 
Outcome phenotypeGenotypenBaselineDay 57Decrease (%)Regression, β (Se)*P
FPG (mmol/l) Ser/Ser 363 11.1 ± 2.9 7.9 ± 2.4 26.1 ± 20.2 — — 
 Ser/Ala 562 11.0 ± 2.9 7.6 ± 2.0 27.9 ± 18.9 2.8 (1.6) 0.076 
 Ala/Ala 224 11.5 ± 3.3 7.6 ± 2.5 31.6 ± 19.8 7.7 (1.9) <0.001 
2-h plasma glucose (mmol/l) Ser/Ser 269 18.9 ± 4.7 15.2 ± 5.9 22.3 ± 22.8 — — 
 Ser/Ala 404 18.4 ± 4.7 14.0 ± 4.1 23.3 ± 23.4 10.8 (3.3) 0.001 
 Ala/Ala 157 18.8 ± 4.4 13.9 ± 4.4 27.6 ± 20.3 11.9 (4.1) 0.003 
A1C (%) Ser/Ser 151 8.4 ± 1.9 7.0 ± 1.5 14.2 ± 17.6 — — 
 Ser/Ala 251 8.3 ± 2.0 6.8 ± 1.2 15.8 ± 15.3 1.9 (1.4) 0.195 
 Ala/Ala 106 8.7 ± 2.0 7.0 ± 1.4 17.4 ± 13.5 3.5 (1.8) 0.060 

Data are means ± SD unless otherwise indicated.

*

Multiple line regression model, outcome variables were percent decrease in FPG, 2-h plasma glucose, and A1C, respectively. The analysis adjusted for age, gender, total gliclazide dose, and baseline HOMA-B and HOMA-IR. β (Se), regression coefficient (SE) for genotype using Ser/Ser as reference.

Close Modal

or Create an Account

Close Modal
Close Modal